Raymond James Reinstates Outperform on Compass Therapeutics, Announces $9 Price Target

Benzinga · 07/01 15:42
Raymond James analyst Sean McCutcheon reinstates Compass Therapeutics (NASDAQ:CMPX) with a Outperform and announces $9 price target.